1. European Association for the Study of the Liver. 2018; EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 69:182–236. DOI:
10.1016/j.jhep.2018.03.019. PMID:
29628281.
2. Hucke F, Pinter M, Graziadei I, et al. 2014; How to STATE suitability and START transarterial chemoembolization in patients with intermediate stage hepatocellular carcinoma. J Hepatol. 61:1287–1296. DOI:
10.1016/j.jhep.2014.07.002. PMID:
25016222.
Article
3. Han G, Berhane S, Toyoda H, et al. 2020; Prediction of survival among patients receiving transarterial chemoembolization for hepatocellular carcinoma: a response-based approach. Hepatology. 72:198–212. DOI:
10.1002/hep.31022. PMID:
31698504. PMCID:
PMC7496334.
Article
4. Kadalayil L, Benini R, Pallan L, et al. 2013; A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer. Ann Oncol. 24:2565–2570. DOI:
10.1093/annonc/mdt247. PMID:
23857958. PMCID:
PMC4023407.
Article
5. Piscaglia F, Ogasawara S. 2018; Patient selection for transarterial chemoembolization in hepatocellular carcinoma: importance of benefit/risk assessment. Liver Cancer. 7:104–119. DOI:
10.1159/000485471. PMID:
29662837. PMCID:
PMC5892363.
Article
6. Cappelli A, Cucchetti A, Cabibbo G, et al. 2016; Refining prognosis after trans-arterial chemo-embolization for hepatocellular carcinoma. Liver Int. 36:729–736. DOI:
10.1111/liv.13029. PMID:
26604044.
Article
7. Hucke F, Sieghart W, Pinter M, et al. 2014; The ART-strategy: sequential assessment of the ART score predicts outcome of patients with hepatocellular carcinoma re-treated with TACE. J Hepatol. 60:118–126. DOI:
10.1016/j.jhep.2013.08.022. PMID:
24012941.
Article
8. Adhoute X, Penaranda G, Naude S, et al. 2015; Retreatment with TACE: the ABCR SCORE, an aid to the decision-making process. J Hepatol. 62:855–862. DOI:
10.1016/j.jhep.2014.11.014. PMID:
25463541.
Article